- JP-listed companies
- Income statement
【JP:4892】Income statement
Market cap
¥5.1B
P/E ratio
-5.6x
Cyfuse develops 3D tissues and organs made entirely from human cells for regenerative medicine, drug discovery, and medical device applications.
| 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 79 | 26 | 122 | 137 | 708 | 374 | 61 | 54 | 231 |
| Revenue growth (%) | - | ||||||||
| Cost of revenue | - | - | - | 70 | 138 | 133 | 23 | 38 | 117 |
| Gross profit | - | - | - | 67 | 571 | 241 | 38 | 17 | 114 |
| Gross margin (%) | - | - | - | ||||||
| Operating margin (%) | - | - | - | ||||||
| Operating expenses | - | - | - | 439 | 500 | 667 | 735 | 913 | 942 |
| Operating income | - | - | - | -372 | 71 | -425 | -697 | -896 | -828 |
| Income before tax | -356 | -384 | -369 | -327 | 145 | -433 | -586 | -870 | -761 |
| Pretax margin (%) | -450.8 | -1,468.5 | -303.3 | -238.2 | 20.5 | -115.7 | -959.2 | -1,597.4 | -329.4 |
| Provision for income taxes | - | - | - | 2 | 2 | 2 | 3 | 2 | 3 |
| Effective tax rate (%) | - | - | - | ||||||
| Net income | -398 | -386 | -372 | -330 | 143 | -474 | -589 | -872 | -763 |
| Net income margin (%) | |||||||||
| Earnings per share | -397,698.79 | -385,245.79 | -371,133.37 | -658.34 | 285.53 | -177.67 | -75.42 | -108.34 | -86.78 |
| Dividend per share | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | ||||||
| EBITDA margin (%) | - | - | - |